Overview

Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder

Status:
Completed
Trial end date:
2018-05-07
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine if intranasal ketamine shows initial evidence of safety, tolerability and efficacy for the treatment of social impairment in individuals with Autism Spectrum Disorder.
Phase:
Phase 1
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Collaborators:
Cures Within Reach
Roivant Sciences, Inc.
Treatments:
Ketamine